Sandoz Group

Sandoz Group ROCE

The Return on Capital Employed (ROCE) of Sandoz Group (SDZ.SW) as of Oct 26, 2026 is 15.18 %. In the previous year, Return on Capital Employed (ROCE) was 16.66 % — a change of -8.84% (lower).

ROCE

15.18 %

YoY

-8.84%

Last updated:

In 2025, Sandoz Group's return on capital employed (ROCE) was 15.18 %, a -8.84% increase from the 16.66 % ROCE in the previous year.

The Sandoz Group ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2020
10.40 USD
Jan 1, 2021
17.10 USD
Jan 1, 2022
112,754.25 USD
Jan 1, 2023
4.33 USD
Jan 1, 2024
16.66 USD
Jan 1, 2025
15.18 USD
The Sandoz Group ROCE history
YEARROCEYoY
15.18 %-8.84%
16.66 %+284.36%
4.33 %-100.00%
112,754.25 %+659,335.28%
17.10 %+64.40%
10.40 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sandoz Group Stock analysis

What does Sandoz Group do? Sandoz Group AG generates revenue through its Generics and Biosimilars businesses. The Generics business develops, manufactures, and markets active ingredients and finished dosage forms of small molecule pharmaceuticals, as well as anti-infective finished dosage forms and active pharmaceutical ingredients. The Biosimilars business develops, manufactures, and markets protein-based biological products similar to already approved biological medicines. Sandoz serves customers worldwide across therapeutic areas including cardiovascular, central nervous system, oncology, anti-infectives, pain, and respiratory treatments. Its product portfolio covers all major treatment areas for patient care. The company's Generics business focuses on small molecule pharmaceuticals and anti-infectives, while Biosimilars targets protein-based biological products. Both segments serve global healthcare markets with products for various therapeutic areas. Sandoz's customers are healthcare providers and institutions worldwide that require pharmaceutical solutions for diverse medical conditions. Sandoz Group AG's revenue streams come from the sale of generics and biosimilars across all therapeutic areas. The company's products are distributed globally to healthcare systems and providers who treat patients in cardiovascular, central nervous system, oncology, anti-infectives, pain, and respiratory conditions. The firm's business model relies on developing and commercializing both small molecule pharmaceuticals and biological products to meet global healthcare needs. Sandoz Group is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Sandoz Group's Return on Capital Employed (ROCE)

Sandoz Group's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Sandoz Group's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Sandoz Group's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Sandoz Group’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Sandoz Group stock

Return on Capital Employed (ROCE) of Sandoz Group is 15.18 % in 2025.

Return on Capital Employed (ROCE) of Sandoz Group changed from 16.66 % to 15.18 %, representing a -8.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Sandoz Group since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Sandoz Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Sandoz Group

All Key Metrics — Sandoz Group